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ABSTRACT
Background. Disease control in anti-neutrophil cytoplasmic
antibody (ANCA) associated vasculitis (AAV) with immuno-
suppression is effective but burdened by adverse events, espe-
cially infections. The study goal was to evaluate risks and types
of infections in patients with AAV.
Methods. Biopsy-proven AAV patients (diagnosed 1/1991–6/
2011) followed in an inception cohort were evaluated for adverse
events. Severe infections (requiring intravenous antibiotics, inten-
sive care unit, or causing death) were recorded. Infection number
was grouped as none, 1–2 or ≥3. Cox regression was used to esti-
mate hazard ratios with 95% confidence intervals.
Results. A total of 489 patients (median age 59; 47% female, 55%
myeloperoxidase-ANCA) were followed for 2.8 years (median).
At 1, 2 and 5 years cumulative incidence of infection was 51, 58
and 65% and severe infection was 22, 23 and 26%. Pulmonary
and upper respiratory infections were most common (42 and
30% ever experienced each, respectively), highest in the first
3 months. Staphylococcus aureus was most frequently seen
among positive cultures (41%, 78 S. aureus/192 total positive cul-
tures), and only one Pneumocystis jiroveci pneumonia (6 weeks
into treatment). All-cause death in 12 months was associated with
infections (% deaths: 0 infections 3%; 1–2 infections 10%, ≥3 in-
fections 13%, P = 0.002). Controlling for age, sex and kidney
function, patients with severe infections were 4.2 times more
likely to die within 12 months (95% CI 2.0–8.7; P = 0.001).
Conclusions. More infections increase the risk of a severe in-
fection which increases risk of all-cause mortality. Respiratory
and S. aureus infections are dominant. Targeted prophylactic
therapy could decrease morbidity.
Keywords: ANCA, glomerulonephritis, immunosuppression,
outcomes, risk factors
INTRODUCTION
Treatment of antineutrophil cytoplasmic antibody (ANCA)
associated vasculitis (AAV) has focused on suppression of the
immune response and control of the pathogenesis of disease
[1–5]. Currently, 80–85% of patients with AAV reach remis-
sion with effective immunosuppressive strategies [6–9]. This
disease control has an associated burden of infection-related
mortality during the 12 months following diagnosis of AAV
[10]. AAV has transformed from a process likely to cause
acute death [4] to one of achieving and preserving remission.
However, the use of immunosuppressive agents places patients
at risk for infections. Although there was hope that rituximab
would reduce adverse events when compared with cyclophos-
phamide, this has not been the case [11–14]. The current chal-
lenge is to reduce long-term morbidity and mortality by
tailoring immunosuppression to limit infections and other
adverse events without increasing relapse.
© The Author 2015. Published by Oxford University Press
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The goal of this study was to use a prospective inception
cohort of AAV followed since 1991 to clearly define patient-
specific factors that influence infections as well as the types of
organisms causing and temporal nature of these infections. In-
sights gained could elucidate mechanisms to improve out-




Patients from the Glomerular Disease Collaborative Network
(GDCN) inception cohort were included in this study if they
had AAV diagnosed between 01 January 1991 to 06 January
2011. The GDCN is a longitudinal, glomerular disease patient
registry and bio bank repository that has been in existence for
over 30 years and primarily enrolls patients from southeastern
USA, previously described [9, 15]. Patients required diagnostic
biopsy with evidence of pauci-immune glomerulonephritis or
small vessel vasculitis with or without granulomatous inflamma-
tion. All patients had positive ANCA determination by immuno-
fluorescence (IF) microscopy or antigen-specific, enzyme-linked
immunosorbent assay (ELISA). ANCA positivity was classified
as cytoplasmic ANCA (cANCA) and/or proteinase 3-ANCA
(PR3-ANCA), or perinuclear ANCA (pANCA) and/or myelo-
peroxidase-ANCA (MPO-ANCA). A positive pANCA alone re-
quired a concurrent negative antinuclear antibody test result.
Age was noted at the time of initial diagnosis. Diagnostic
disease categories were defined according to the modified
Chapel Hill Consensus Conference nomenclature, and desig-
nated as granulomatosis with polyangiitis (GPA), eosinophilic
granulomatosis with polyangiitis (EGPA), microscopic polyan-
giitis (MPA), or pauci-immune necrotizing and/or crescentic
glomerulonephritis (GN) without overt signs of systemic
vasculitis [16, 17].
Infections and adverse events were obtained from medical
records (see list in Table 1). Severe infections were defined as
any infection requiring intravenous antibiotics, hospitalization
or resulting in an infection-related death. Venothromboem-
bolic events (VTE) were assumed to be related to pathogen-
icity of disease [18–21]. Relapse was defined as the appearance
of dysmorphic red blood cells in the urine or signs of active
vasculitic lesions in any other organ deemed severe enough to
warrant a change in therapy. Proteinuria alone was not consid-
ered indicative of active glomerulonephritis. We also evaluated
end-stage kidney disease (ESKD) and death from any cause.
Patients were excluded for ESKD from the time of initial diag-
nosis (Figure 1).
We screened 547 patients and excluded 58 (ESKD at initial
presentation or insufficient information) (Figure 1). This left
489 patients who were evaluated for overall occurrence of
adverse events. To learn more about the first 2 years after initial
diagnosis, we then evaluated the subset of patients who had a
full 12 months of follow-up and evaluated the outcomes within
this timeframe (‘1-year cohort’, n = 421, Figure 1). We then
performed this same evaluation including the subset of patients
with a full 24 months of follow-up (‘2-year cohort’, n = 374,
Figure 1). Of note, patients who died from any cause were in-
cluded in both the 1-year and 2-year cohort. Evaluation of pa-
tients within these set intervals of follow-up allowed us to study
only those patients with equal amounts of time to have the
events of interest. Those who reached ESKD within these time-
frames were censored at the time of ESKD due to potential dif-
ferences in reasons for adverse events and death following
initiation of renal replacement therapy. Estimated glomerular
filtration rate (eGFR, mL/min/1.73 m2) at diagnosis was calcu-
lated using the abbreviated Modification of Diet in Renal
Disease (MDRD) equation [22].
Patient participation was approved by the University of
North Carolina Institutional Review Board, with informed
consent provided by all patients for long-term follow-up of
medical information.
Therapy
Months and number of infusions of intravenous (IV) im-
munosuppressive treatment were recorded. Rituximab therapy
was recorded by course. For total cyclophosphamide exposure
1 IV infusion was considered 1 month of therapy and added to
number of months of oral cyclophosphamide therapy. Patients
in this cohort were most commonly treated with a regimen
that included methylprednisolone 500 mg IV daily for 3 days,
prednisone 60 mg daily for 4 weeks followed by a 12 week
taper, cyclophosphamide 0.5–1 g/m2 monthly or daily oral 2
mg/kg for 3–6 months, azathioprine 2 mg/kg for 12 months,
mycophenolate mofetil 1 g twice a day or rituximab therapy
given as 1 g IV on day 1 and 15 (1 course) or 375 mg/m2 IV
weekly for 4 weeks (1 course). The combination of immuno-
suppressive medications was decided by the attending phys-
ician and not per specific protocol for this study. Leukopenia
was defined as white blood cell count of ≤3.0 × 109 per liter.
Prophylactic medications included any trimethoprim sulfa-
methoxazole, dapsone, antiviral or antifungal or any other
antimicrobial agent prescribed for the prevention of infection
in the setting of a known immunocompromized state. The use
of these medications in the setting of an active infection was
not counted as prophylactic therapy.
Statistical analyses
Descriptive statistics included the number (n), percentage
(%), mean and standard deviation (SD), or median with inter-
quartile range (IQR). Comparisons between groups used
Fisher’s exact tests for categorical measures and Wilcoxon
rank sum tests or Kruskal–Wallis tests for continuous mea-
sures. Incidence rates were reported for relapse and infection
as per patient-year or per person month (for the 3 months
pre- and post-relapse) of follow-up using all events, with a
Poisson distribution used to calculate 95% confidence intervals
(95% CI) and standard deviations (SD). Proportional hazards
models were used for multivariable modeling of time to
adverse event, relapse, or death, with hazards ratio (HR), 95%
CI and P-values presented. Proportional odds models were
used to estimate multivariable associations with number of in-
fections (none versus 1–2 versus ≥3 infections), both with and
without weighting severe infections (×2 for each). Logistic re-
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Table 1. Demographics and clinical characteristics for the entire cohort and for the 1- and 2-year cohorts
Total cohort (N = 489) 1-year cohort
(patients followed for
a minimum of 1 year




for a minimum of




Mean ± SD 55 ± 19 55 ± 19 56 ± 19
Median (IQR) 59 (45, 70) 59 (46, 70) 59 (46, 71)
Sex
Female 232 (47%) 200 (48%) 182 (49%)
ANCA specificity
MPO/P-ANCA 269 (55%) 231 (55%) 198 (53%)
PR3/C-ANCA 216 (44%) 187 (44%) 173 (46%)
Both PR3- and MPO-ANCA 2 (0.4%) 1 (0.2%) 1 (0.3%)
ANCA Positive, no specificity 2 (0.4%) 2 (0.5%) 2 (0.5%)
Clinical diagnosis
GPA 122 (25%) 113 (27%) 103 (28%)
MPA 257 (53%) 219 (52%) 203 (54%)
PICGN 105 (22%) 84 (20%) 64 (17%)
EGPA 5 (1%) 5 (1%) 4 (1%)
Organ involvement
Kidney 462 (95%) 396 (94%) 350 (94%)
Lungs 252 (52%) 215 (51%) 196 (52%)
ENT 188 (39%) 170 (40%) 155 (41%)
Skin 108 (22%) 97 (23%) 92 (25%)
GI 46 (9%) 38 (9%) 33 (9%)
eGFR at onset (mL/min/1.73 m2)
Median (IQR) 19 (12, 41) 21 (12, 42) 22 (12, 43)
Follow-up (years)
Median (IQR) 2.8 (1.2, 6.2) 3.4 (1.9, 7.1) 3.8 (2.4, 7.5)
Death (any cause) over the entire follow-up, n (%) 128 (26%) 119 (28%) 116 (31%)
Death from infection over the entire follow-up, n (%) 15 (3%) 15 (4%) 15 (4%)
N (%) with at least 1 infection ever 376 (77%) 335 (80%) 307 (82%)
N (%) with at least 1 severe infection evera 114 (23%) 91 (22%) 96 (26%)
N (%) with at least 1 relapse ever 194 (40%) 194 (46%) 194 (52%)
N (%) ESKD over entire follow-up 94 (19%) 69 (16%) 60 (16%)
Infusions of methylprednisolone
N 305 260 234
Median (IQR) 3 (3, 4) 3 (3, 5) 3 (3, 6)
Months of prednisone
N 398 343 305
Median (IQR) 11 (5, 21) 12 (5, 23) 12 (6, 25)
Months of IV cyclophosphamide
N 294 255 225
Median (IQR) 6 (3, 6) 6 (3, 7) 6 (3, 7)
Months of daily oral cyclophosphamide
N 201 182 161
Median (IQR) 7 (3, 14) 8 (4, 14) 8 (4, 15)
Courses of rituximab
N 90 88 85
Median (IQR) 2 (2, 4) 2 (2, 4) 2 (2, 4)
Months of azathioprine
N 130 121 114
Median (IQR) 9 (2, 21) 9 (2, 21) 11 (2, 24)
Months of mycophenolate mofetil
N 154 146 139
Median (IQR) 14 (4, 34) 16 (5, 38) 18 (5, 38)
Months of methotrexate
N 39 38 37
Median (IQR) 19 (7, 30) 20 (7, 30) 20 (7, 30)
Venothromboembolic event, n (%) 53 (11%) 43 (10%) 40 (11%)
Cancerb, n (%) 65 (13%) 61 (15%) 56 (15%)
Avascular necrosis, n (%) 8 (2%) 8 (2%) 8 (2%)
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factors for severe infections in the 1-year and 2-year cohorts
separately. For proportional odds and logistic models, odds
ratio (OR), 95% CI and P-values are presented. Analyses were
conducted using SAS software (version 9.3 SAS Institute, Cary,
NC, USA). Exact P-values were reported with a two-sided
P-value of <0.05 considered statistically significant.
RESULTS
Four hundred and eighty-nine patients with adequate follow-
up available, diagnosed after 1991, and not designated as
having ESKD at time of diagnosis were eligible for this study
(Table 1, Figure 1). Forty-seven percent of the population was
female and median age was 59 years (IQR 45, 70). Fifty-three
percent of patients were diagnosed with MPA and 55% were
MPO-ANCA positive (Table 1). Median follow-up of the
cohort was 2.8 years (IQR 1.2, 6.2). Cumulative immunosup-
pression exposure is listed in Table 1.
Cumulative incidence at 1, 2 and 5 years of any infection
was 51, 58 and 65%, severe infection was 22, 23 and 26%, and
relapse was 14, 27 and 41%, respectively, which are unadjusted
estimates (Figure 2). One hundred and sixteen severe infec-
tions occurred in 52 patients after 12 months from start of
Table 1. Continued
Total cohort (N = 489) 1-year cohort
(patients followed for
a minimum of 1 year




for a minimum of
2 years or died
within 2 years)
(N = 374)
Weight gain, yes n (%) from prednisone start to finish 174 (36%) 158 (38%) 140 (37%)
Neuropsychiatric events, n (%) 77 (16%) 68 (16%) 59 (16%)
Cataracts, n (%) 37 (8%) 37 (9%) 35 (9%)
Myocardial Infarction, n (%) 19 (4%) 18 (4%) 17 (5%)
Gastrointestinal bleed, n (%) 53 (11%) 45 (11%) 41 (11%)
History of diabetes mellitus, n (%) 38 (8%) 30 (7%) 25 (7%)
Steroid-induced diabetes mellitus, n (%) 148 (30%) 106 (25%) 103 (29%)
Stroke, n (%) 16 (3%) 15 (4%) 15 (4%)
Myopathy, n (%) 44 (9%) 42 (10%) 37 (10%)
Acne, n (%) 32 (7%) 28 (7%) 23 (6%)
SD, standard deviation; IQR, Interquartile range; ANCA, antineutrophil cytoplasmic antibody; MPO, myeloperoxidase; P, perinuclear; PR3, proteinase 3; C, cytoplasmic; GPA,
granulomatosis with polyangiitis; MPA, microscopic polyangiitis; PICGN, pauci-immune crescentic glomerulonephritis without systemic vasculitis (renal limited disease); EGPA,
eosinophilic granulomatosis with polyangiitis; ENT, ear nose and throat; GI, gastrointestinal; ESKD, end-stage kidney disease; IV, intravenous.
aSevere infection defined as any infection requiring intravenous antibiotics, hospitalization or resulting in an infection-related death.
bAll cancers including non-melanomatous skin cancers that occurred after immunosuppression administration.
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therapy. Of these, 32 (28%) occurred during treatment for
relapse and 84 (72%) occurred during maintenance therapy.
Incidence of ESKD and death are also shown in Figure 2, with
17% of the patients progressing to ESKD after diagnosis and
7% dying in 5 years. Other adverse events and complications
of therapy are listed in Table 1 and are reported as ever present
over the duration of follow-up.
Infections in the 1-year and 2-year cohorts
Of the 421 patients included in the detailed 1-year cohort,
237 (56%) experienced at least one infection during that year;
192 (46%) had 1–2 infections and 45 (11%) had ≥3 infections
(Table 2). An increased number of infections per patient was
associated with increasing age and steroid-induced diabetes
mellitus (DM) (Table 2). Females and patients with more
leukopenic episodes had a trend for more infections (Table 2).
In multivariable proportional hazards models of increasing
numbers of infections age (OR 1.01, 95% CI 1.00, 1.02, P =
0.021) and female sex (OR 1.75, 95% CI 1.18, 2.58, P = 0.005)
were significant predictors, but not steroid-induced diabetes.
Results were the same if severe infections were weighted more
heavily than other infections and also if controlling for leuko-
penic episodes and eGFR, neither of which was associated
with number of infections. Infections were associated with
death from any cause and relapse within 12 months (Table 2).
Greater number of infections was associated with a greater
likelihood of severe infection. Infection number was not differ-
ent between those who were and were not given prophylactic
therapy. Of note, 90% of those given prophylactic therapy
were treated with trimethoprim sulfamethoxazole.
In the 2-year cohort (n = 374), 251 (67%) experienced at
least one infection during that timeframe; 169 (45%) had 1–2
infections and 82 (22%) had ≥3 infections (Table 3). Infection
results of the 2-year cohort were similar to patients followed
for at least 12 months, except that female sex was more strong-
ly associated with increasing number of infections (0 infec-
tions: 39% female, 1–2 infections: 52% female, ≥3 infections:
56% female, P = 0.03 versus males) (Table 3). Infections re-
mained associated with death and relapse in the 2-year cohort
(Table 3). A trend for an association between more leukopenic
episodes and more infections remained (P = 0.06). Multivari-
able associations were virtually the same as in the 1-year cohort
with age and female sex remaining predictors, but not other
measures, and results were not changed when weighting severe
infections (data not shown).
To assess if infections predominantly occurred post-relapse
due to additional immunosuppressive therapy, the incidence
of infections 3 months prior to relapse and 3 months post-
relapse was determined. First relapse was used to avoid re-
peated immunosuppressive treatments with multiple relapses.
Among 88 patients who relapsed within 2 years, there were 15
infections in the 3 months prior and 25 in the 3 months post-
relapse, with incidence rates of infection: 0.056 (0.031, 0.083)
per person per month in the 3 months prior to relapse and
0.095 (0.063, 0.126) per person per month in the 3 months
after relapse, P-value = 0.078. The trend for fewer infections
prior to relapse does not rule out the potential that infections
may contribute to initiating a relapse.
In the 2-year cohort, 96 experienced at least one severe infec-
tion within those 2 years (Table 4). Advancing age, female sex,
steroid-induced diabetes and lower eGFR at diagnosis were
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associated with severe infections compared with no infections,
while more leukopenic episodes showed a trend of an association
with any infection (severe or not) compared with those with no
infection. In a multivariable model of predictors of severe infec-
tions, age was no longer statistically significant, but the following
measures remained important: female gender (OR 1.83 (95% CI
1.20, 2.81, P = 0.006), steroid-induced diabetes (OR 1.91 (95% CI
1.23, 2.98, P = 0.004) and lower eGFR (OR 0.990 (95% CI 0.981,
0.999, P = 0.028). Patients who had at least one severe infection
were more likely to die from any cause compared with those with
no infections or with those having non-severe infections
(Table 4). By multivariable analysis controlling for age, sex, and
eGFR, severe infection remained independently associated with
death from any cause (HR = 3.75, 95% CI 1.99–7.03, P < 0.0001).
Steroid-induced diabetes, corticosteroid treatment
and severe infections
The association between steroid-induced diabetes, cortico-
steroid treatment and severe infections was further explored.
Patients developed steroid-induced diabetes in a median of
Table 2. (N = 421) Demographics and outcomes of patients in the 1-year cohort by infection number
0 infections in first
12 months (N = 184)
1–2 infections in first
12 months (N = 192)
≥3 infections in first
12 months (N = 45)
Pa
Mean age years 0.02
Mean ± SD 53 ± 19 57 ± 19 59 ± 17
Median (IQR) 57 (45, 66) 60 (47, 72) 66 (48, 73)
Female sex 77 (42%) 97 (51%) 26 (58%) 0.08
Mean number of episodes of Leukopenia within 12 months 0.09
N 64 80 25
Mean ± SD 0.9 ± 0.9 1.1 ± 1.1 1.2 ± 0.9
Median (IQR) 1 (0, 1) 1 (0, 1) 1 (1, 1)
eGFR at onset (mL/min/1.73 m2)
Median (IQR)
22 (13, 45) 20 (11, 41) 18 (13, 33) 0.24
Diabetes mellitus induced by steroids within 12 months 34 (19%) 52 (27%) 20 (44%) 0.001
Mean number of relapses within 12 months 0.01
N 92 85 17
Mean ± SD 0.2 ± 0.5 0.5 ± 0.6 0.4 ± 0.5
Median (IQR) 0 (0, 1) 0 (0, 1) 0 (0, 1)
Prophylaxis given within 12 months 47 (26) 46 (24%) 14 (31%) 0.59
Severe infectionb within 12 months 0 (0%) 69 (36%) 29 (64%) <0.0001
Death from any cause within 12 months 5 (3%) 20 (10%) 6 (13%) 0.002
SD, standard deviation; IQR, interquartile range.
aP-values were calculated by Fisher exact test for categorical variables and Wilcoxon two samples for continuous variables.
bSevere infection defined as any infection requiring intravenous antibiotics, hospitalization or resulting in an infection-related death.
Table 3. Demographics and outcomes of patients in the 2-year cohort by infection number (N = 374)
0 infections in first
24 months (N = 123)
1–2 infections in first
24 months (N = 169)
≥3 infections in first
24 months (N = 82)
Pa
Mean age years 0.01
Mean ± SD 52 ± 19 58 ± 18 57 ± 18
Median (IQR) 56 (44, 65) 61 (48, 72) 63 (47, 71)
Female Sex 48 (39%) 88 (52%) 46 (56%) 0.03
Mean number of episodes of Leukopenia within 24 months 0.06
Mean ± SD 1 ± 0.9 1.3 ± 1 1.5 ± 1
Median (IQR) 1 (0, 1) 1 (1, 2) 1 (1, 2)
eGFR at onset (mL/min/1.73 m2)
Median (IQR2)
24 (14, 52) 22 (11, 41) 20 (14, 39) 0.14
Diabetes mellitus induced by steroids within 24 months 24 (20%) 45 (27%) 34 (42%) 0.003
Mean number of relapses within 24 months 0.005
N 71 79 44
Mean ± SD 0.6 ± 0.7 0.9 ± 0.8 0.9 ± 0.6
Median (IQR) 0 (0, 1) 1 (0, 1) 1 (1, 1)
Prophylaxis given within 24 months 32 (26%) 47 (28%) 29 (35%) 0.32
Severe infectionb within 24 months 0 (0%) 52 (31%) 44 (54%) <0.0001
Death from any cause 5 (3%) 20 (10%) 6 (13%) 0.13
SD, standard deviation; IQR, interquartile range.
aP-values were calculated by Fisher exact test for categorical variables and Wilcoxon two samples for continuous variables.
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1 month (28.5 days; IQR: 3 days to 4.0 months). In the 2-year
cohort, patients who developed steroid-induced diabetes were
more likely to receive pulse methylprednisolone for their initial
treatment for vasculitis (58%) compared with those who did
not develop steroid-induced diabetes (44%, P = 0.006). There
was no difference in months of oral prednisone between those
who did and did not develop steroid-induced diabetes (P = 0.92).
Among those who did not receive methylprednisolone, 31%
(14/48) with diabetes had a least one severe infection versus
20% (30/147) among those without diabetes (P = 0.17). Among
those who did receive methylprednisolone, 45% (29/65) with
diabetes had at least one severe infection versus 19% (22/114)
among those without diabetes (P = 0.0005).
Timing of infections following immunosuppression
Pulmonary and upper respiratory infections were the most
common, followed by systemic/organ threatening infections
and urinary tract infections/pyelonephritis (Figure 3a). The
greatest numbers of infections occurred in the first 3 months
(Figure 3a). The time line of when infections occurred within
the first 24 months is presented by infection type in Figure 3a.
Systemic/organ threatening infections included sepsis or any in-
fection that caused an organ-based infection such as meningitis,
endocarditis and orbital infection. Viral infections encompassed,
but were not limited to, herpes simplex virus, varicella-zoster
virus and cytomegalovirus. Adenovirus and upper respiratory
virus infections were encompassed within the upper respira-
tory infection (URI) categorization.
Causative organisms for infections
To understand infectious etiology, we reviewed 128 patients
who had an available culture within 24 months following treat-
ment initiation. Of these, 95 patients had 249 positive cultures
from urine (38%), the upper respiratory tract (15%), blood
(13%), lung (10%), skin (4%), other sites (5%) or from an un-
specified site (15%). Twenty-nine of the 249 (12%) cultures
were from severe infections. Results are broken down as a
temporal outline in 3-month intervals across 24 months
(Figure 3b). Staphylococcus aureus was the most frequently
grown infectious agent in culture (34%, 85 cultures positive for
S. aureus/249 total positive cultures) and was found most com-
monly in urine (54% of those positive for S. aureus) and the
upper respiratory tract (16%), but also in blood, lungs, skin
and stool (<6% each), with 10% from unknown sites. Eighteen
of the 85 (21%) S. aureus cultures were among patients who
had received trimethoprim sulfamethoxazole as prophylaxis.
Twelve (14%) of the 85 S. aureus cultures were from infections
classified as severe. Gram negative organisms (25%, 64/249)
and yeast (16%, 40/249) were the next most common categor-
ies (Figure 3b). There was one positive culture for Pneumocys-
tis jiroveci pneumonia 6 weeks following treatment initiation,
and this patient had not received prophylactic therapy.
Infection differences by gender
Types of infections were explored by sex to understand the
trends for more total infections and severe infections in females
compared with males. Among the entire cohort, women were
far more likely than men to have urinary tract infections/pyelo-
nephritis (73/232 = 32 versus 32/257 = 13%, respectively; P <
0.0001). Upper respiratory infections were seen in 9% more of
the women than men (35 versus 26%, respectively; P = 0.02),
but all other types of infections were similar by sex.
Influence of immunosuppression on infections
Within 2 years of follow-up, patients with severe infection
had less exposure to cyclophosphamide [median 5 months
Table 4. Comparison of demographics and outcomes of patients with no infections, non-severe infections and severe infections among those in the 2-year










Mean ± SD 52 ± 19 56 ± 18 59 ± 18
Median (IQR) 56 (44, 65) 60 (45, 71) 65 (50, 72)
Female sex 48 (39%) 77 (50%) 57 (59%) 0.011
ANCA specificity 0.79
MPO/P-ANCA 65 (53%) 82 (53%) 51 (53%)
PR3/C-ANCA 58 (47%) 72 (47%) 43 (45%)
Both PR3- and MPO-ANCA 0 (0%) 0 (0%) 1 (1%)
ANCA Positive, no specificity 0 (0%) 1 (1%) 1 (1%)
Diabetes mellitus, steroid induced, within 24 months 24 (20%) 36 (23%) 43 (45%) <0.0001
Mean number of episodes of Leukopenia within 24 months 0.099
N 44 64 45
Mean ± SD 1 ± 0.9 1.4 ± 1.2 1.2 ± 0.8
Median (IQR) 1 (0, 1) 1 (1, 2) 1 (1, 1)
eGFR at onset (ml/min/1.73 m2)
Median (IQR2)
24 (14, 52) 25 (12,46) 17 (11, 30) 0.005
Incidence of relapse within 24 months (per-person-year) 0.042 0.038 0.034
Death from any cause within 24 months 8 (7%) 9 (6%) 24 (25%) <0.0001
SD, standard deviation; IQR, interquartile range; ANCA, antineutrophil cytoplasmic antibody; MPO, myeloperoxidase; P, perinuclear; PR3, proteinase 3; C, cytoplasmic.
aSevere infection defined as any infection requiring intravenous antibiotics, hospitalization or resulting in an infection-related death.
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(IQR: 2, 9)] compared with those who never experienced
severe infection [median 6 months (IQR: 4,11); P = 0.008].
Duration of all other immunosuppressive therapies was
similar between those with and without severe infection.
Months of exposure to cyclophosphamide, prednisone, MMF,
azathioprine, methotrexate, or infusions of methylpredniso-
lone or rituximab was not different by number of infections (0
versus 1–2 versus ≥3). However, months of combined expos-
ure to MMF, azathioprine or methotrexate in the 24-month
cohort was higher among those who had no infections
[median 14 months (IQR: 11, 18)] and those who had ≥3 in-
fections [median 13 months (IQR: 7, 17)] compared with
those who had 1 or 2 infections [median 8 months (IQR:
3,14); P = 0.0001]. These trends were similar in the 12-month
cohort. Due to the dynamic interplay of treatment choices
made in response to patients experiencing an infection, which
usually involved decreasing, stopping or changing treatment,
modeling of duration of immunosuppression therapy across
infectious outcomes was not pursued.
Death
Cumulative incidence of death in the total cohort at 1, 2
and 5 years was =1, 2 and 7%, respectively, which are
unadjusted estimates that are censored for loss of follow-up
(Figure 2). Within the 1-year cohort, 31 of 421 (7%) died
within 12 months; 29% with active disease, 13% from infec-
tious complications, 29% from various causes after reaching
ESKD, 10% from cardiovascular events and 19% from
unknown causes prior to reaching ESKD. Advanced age was
associated with death within 12 months (alive median age 57
years [IQR 45, 68]), versus those who died median age 72
[IQR 66, 74], P = < 0.0001), as was lower eGFR (alive median
eGFR 22 mL/min/1.73 m2 [IQR 12, 43], versus those who died
(median eGFR 12 [IQR 8, 20], P = 0.0002). Severe infection
within 12 months was associated with death: 19% (19/98) with
severe infections died compared with 4% (12/323) with no
severe infection; P≤ 0.0001. In multivariable analysis control-
ling for age, sex, eGFR and severe infection, age and severe in-
fection remained associated with death within 12 months: HR
for age/1-year increase = 1.06 (95% CI 1.02, 1.09, P = 0.0011);
HR for severe infection = 4.20 (95% CI 2.0, 8.7; P = 0.001).
There was a trend for lower eGFR to predict death (HR = 0.97,
95% CI 0.94, 1.0, P = 0.066). ANCA serotype, sex and involve-
ment of specific organs were not associated with death at 12
months. Ten additional patients died between 12 and 24 months
for a total of 41 deaths in 24 months. Results were virtually the
same for the impact of age and severe infection on death at
24 months (Table 5).
DISCUSSION
Efforts made to control vasculitis through immunosuppres-
sion are associated with the encumbrance of adverse events,
most notably infections that increase patient morbidity and
mortality. This work supports and expands upon mounting
evidence that further reduction of mortality in vasculitis pa-
tients requires a reduction of infections [10, 14, 23–25]. We
have found that increasing numbers of infections increase the
chance of having a severe infection which in turn increases
risk of all-cause mortality. The risk of mortality from severe
infections, the high risk of infections in the first year and
the predominance of pulmonary infections are similar to a
recent report out of China [25]. However, our study consid-
ers the impact of severe and non-severe infections and
uniquely shows temporal breakdown of organisms causative
of infection.
The quandary of patient management hangs in the balance
of controlling or preventing recurrence of active vasculitis in
the face of increasing risk of infections from therapy. Death
rates in vasculitis prior to the use of immunosuppression were
85% at 5 years [1–4] and it was not until effective immunosup-
pressive strategies were defined [5, 26] that vasculitis morphed
from an acute cause of death to a disease of chronic morbidity
[10, 23, 27]. Understanding the intertwined immunosuppression-
associated outcomes of maintaining quiescent disease and also
limiting infections suggests the need for patient-specific treat-
ment strategies.
It is accepted that infections are related to immunosuppres-
sion. Within the first 12 months following diagnosis, 56% of
our patient population had some form of infection and 23%
F IGURE 3 : Number of infections experienced within 3 month time
intervals from initiation of first therapy out to 24 months by (a) infec-
tion type and by (b) microbiologic culture type (among 128 patients
cultured with 112 having 192 positive cultures). Multiple infections
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had a severe infection. Finding strategies for prevention or re-
duction of respiratory infections and urinary tract infections/
pyelonephritis, the most common causes of infection in our
cohort, would have a substantial impact on reducing the impact
of infection, including severe infections. Focus on prevention of
severe infection by early detection and treatment with antimi-
crobials and reduction of immunosuppression may also reduce
all-cause mortality.
Prophylactic therapy was not associated with number of
infections in 1 or 2 years in this study, but uniform use of
prophylaxis was not employed. When prescribed, the inten-
tion was to treat with prophylaxis therapy throughout induc-
tion therapy. However, without systematic implementation
and information on compliance, we recognize the true impact
of prophylactic therapy cannot be evaluated. This study pro-
vides a time line of when infections occur and which infectious
agents are causative. Although we did not have comprehensive
culture assessment for all infections, we believe our assessment
of the microbiological data can guide infection prevention and
prophylaxis more specifically in AAV. Importantly, there was
only one case of Pneumocystis jiroveci pneumonia in this
cohort. The highest proportion of positive cultures was
Staphylococcus aureus. Previous studies note an association
between presence of S. aureus and active vasculitis [28]. There
could be a benefit in the first 3–6 months following treatment
initiation to routinely provide patients with prophylaxis
against Staphylococcus aureus, Gram negative and yeast in-
fections. When looking at our treatment pattern for cortico-
steroid administration we note a correlation that we have
previously noted between the time we prescribe corticosteroids
and when infection burden is at its highest [29]. Thrush and
other infections caused by yeast are of greatest burden in the
time frame when steroids are prescribed in the highest doses.
Could a steroid-sparing strategy in AAV control infections in
general and/or those specifically associated with yeast? Also
important to consider is that patients with steroid-induced
diabetes mellitus (DM) are at increased risk of infection, espe-
cially severe infections. Steroid-induced DM occurs in 30% of
our population, and keen attention to reduction in steroids is
vital as they are associated with hyperglycemia as well as infec-
tion [29]. In our cohort the combined impact of methylpredni-
solone use and subsequent steroid-induced diabetes conferred
the strongest risk for severe infections, but an association of
steroid-induced diabetes with severe infection in the absence
of use of methylprednisolone cannot be ruled out. Although
the majority of AAV patients do not end up with steroid-
induced DM, the morbidity this diagnosis carries is significant
and speaks to the importance of steroid-sparing strategies
in AAV to reduce morbidity, as are being piloted in other
autoimmune diseases [30].
While attempts at universal reduction of overall infection
burden are a critical step, we must also be conscious of treating
each patient considering individual risks of adverse events and
disease relapse with an attempt at patient specific/directed
therapy. A difficulty with studying outcomes in vasculitis is
that the outcomes of infection and relapse are intertwined. In-
fections may require a reduction in immunosuppression that
could allow disease activity to emerge. Having an infection can
also directly trigger a relapse [31–33]. Furthermore, increased
immunosuppression used to treat relapse also puts patients at
increased risk for infections.
Additionally, self-monitoring by use of routine urinary dip
sticks for the presence of nitrites and leukocyte esterase to
catch urinary tract infections early and trigger early directed
antibiotic courses would likely be beneficial. Urinary dip stick
use is inexpensive and easy for patients to incorporate into a
self-care routine. Furthermore, routine urinary dip stick home
evaluation could also be extremely valuable in the AAV popu-
lation for early detection of relapse. We commonly recom-
mend that patients with a history of glomerulonephritis on or
off immunosuppression self-monitor with urinary dip-sticks.
This enables the early detection of hematuria or increasing
proteinuria and/or increasing nitrites and leukocyte esterase to
prompt urgent clinic evaluation for relapse or infection. Catch-
ing either event early could prevent significant organ threaten-
ing impacts of the disease and development of severe infections.
Table 5. Number of patients who ever experienced each category of infection over the entire follow-up by cohort (the 12-month cohort, the 24-month
cohort and the total cohort)
Infections 1-Year follow-up
cohorta (N = 421)
2-Year follow-up




cohort (N = 232)
Males from total
cohort (N = 257)
P-valuesd
Pulmonary 185 (44%) 175 (47%) 203 (42%) 103 (44%) 100 (39%) 0.23
Upper respiratory 140 (33%) 130 (35%) 148 (30%) 82 (35%) 66 (26%) 0.02
Systemic/organ 106 (25%) 99 (27%) 124 (25%) 59 (25%) 65 (25%) 1.00
Urinary tract/
pyelonephritis
93 (22%) 87 (23%) 105 (22%) 73 (32%) 32 (13%) <0.0001
Viral (N = 80)% 78 (19%) 66 (18%) 80 (16%) 45 (19%) 35 (14%) 0.088
Cellulitis (N = 56)% 53 (13%) 49 (13%) 56 (12%) 25 (11%) 31 (12%) 0.67
Thrush (N = 37)% 32 (8%) 28 (8%) 37 (8%) 19 (8%) 18 (7%) 0.73
Otitis media
(N = 28)%
26 (6%) 26 (7%) 28 (6%) 13 (6%) 15 (6%) 1.00
Musculoskeletal
(N = 11)%
11 (3%) 11 (3%) 11 (2%) 4 (2%) 7 (3%) 0.55
Other (N = 7)% 7 (2%) 7 (2%) 7 (1%) 2 (1%) 5 (2%) 0.45
aPatients in this cohort died within or were followed for a complete 12 months.
bPatients in this cohort died within or were followed for a complete 24 months.
cAll patients with all available follow-up included in this cohort.
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This study is not a randomized controlled trial geared at
providing clear-cut guidelines for treatment of AAV, but this
real world experience of an inception cohort allows use of
what we know from our patients in the past to improve how
we treat patients in the future. Level of disease activity includ-
ing treatment resistance and specific complications of vascu-
litis such as lung cavities or damage were not included in our
analysis. Non-uniform treatment and lack of total doses of
each immunosuppressive treatment in the cohort limit our
ability to distinguish differences in infection risk by therapy
type, dose or induction versus maintenance therapy. Further-
more, immunosuppressive treatments are typically reduced or
changed in response to an infection, which is supported by
our data showing that patients with more infections or severe
infections have less exposure to immunosuppression than
those with the lowest infectious burden. Of note, the patients
who had 1–2 infections (rather than 0 or ≥3 infections) had
the least exposure to remission maintenance therapy: MMF,
azathioprine and/or methotrexate. This may indicate that pa-
tients who do not have infections are on remission mainten-
ance longer and patients with higher numbers of infections or
more severe infections are switched from cyclophosphamide
to remission maintenance therapy sooner. Our analysis does
not take into account patient frailty which also potentially
impacts immunosuppression choices and adverse events.
In conclusion, this study provides information on the types
of organisms causing infection and a time line of when these
infections occur. This information allows for more directive
and well-timed prophylactic therapy. This study provides
fodder for constructing future randomized control trials which
can control for variables not possible to control for in an in-
ception cohort study. The focus of clinical care and future
studies regarding therapy for vasculitis requires a shift from
the sole emphasis on attaining and retaining remission
towards a balance of immunosuppression for disease control
and infection reduction. Part of finding this balance may
involve down-titrating immunosuppressive therapy alongside
early relapse monitoring with urine dip sticks and close
follow-up. It is time to take a personalized approach rather
than treating all patients with the same immunosuppression
strategy. We must attempt to avoid the harm from our therap-
ies with overuse above the requirements of disease control.
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